ProGenia Competitors

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs.

Invitae, now part of Labcorp, is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We’re working to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of our mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Within each of us lies information coded in our DNA that can transform our health. Unlocking that potential requires highly specialized, multidisciplinary collaboration. Our world-class genetics experts drive the development of a highly complex system of tools and processes, including robotics, artificial intelligence, machine learning, and software engineering. All of this comes together to provide patients with accurate, reliable results that can help guide decisions across the healthcare journey and potentially change lives today and for the next generation. Our teammates are grounded in a universal sense of urgency and ownership. We believe in the team above the individual and celebrate freedom with accountability. Employees are encouraged to speak up, try new things and make decisions that push us forward. We provide all Invitaens with opportunities to grow and advance, supported by flexible work hours, unlimited paid time off, the ability to work anywhere for many roles and the satisfaction of doing meaningful work. At Invitae, we're putting patients' genetic insights where they belong—at the center of healthcare. And we're doing it together, with you. Join us.

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.